Actively Recruiting
Pancreas Ultrasound Imaging in type1 Diabetes
Led by University of Colorado, Denver · Updated on 2026-05-06
50
Participants Needed
1
Research Sites
183 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The overall goal of this study is to develop and test a novel method involving ultrasound imaging, in order to detect the development of type 1 diabetes. In this study the investigators will first establish a standard operating procedure for measuring pancreas blood flow speed and volume in the pancreas of human subjects. The investigators will then determine 1) whether these pancreas blood flow factors differ between healthy subjects and those who have recently developed type1 diabetes; and 2) how variable measurements are in healthy subjects and subjects that recently developed type1 diabetes, both between subjects and over time. To address these aims the investigators will perform pancreas ultrasound measurements in each subject using an approved injectable 'bubble' contrast agent that allows measurement of pancreas blood flow. The investigators will compare ultrasound measurement with characteristics of the subject's type 1 diabetes, including genetic factors, glucose levels and other circulating factors, as well as other factors that may influence blood flow in the pancreas independent of type1 diabetes. The successful conclusion of this study will indicate whether measuring pancreas blood flow speed/volume will be helpful in monitoring whether type1 diabetes will emerge and thus will allow a large scale study to answer this question.
CONDITIONS
Official Title
Pancreas Ultrasound Imaging in type1 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or non-pregnant female aged 18 to 65 years
- Ability and willingness to fully participate in all study aspects
- Written informed consent obtained and documented
- For control group: no diagnosis of diabetes as per ADA criteria
- For type 1 diabetes group: diagnosis of diabetes within 180 days and presence of specific autoantibodies
- Participants taking metformin must be willing to stop medication two weeks before scans
You will not qualify if you...
- Excessive body size preventing effective pancreas scan
- Presence of exocrine pancreatic diseases like pancreatitis or pancreatic tumors
- Pregnancy or breastfeeding
- Inability to provide informed consent
- Known or suspected allergy to perflutren
- Unstable heart or lung conditions such as recent heart attack or serious arrhythmias
- Use of certain diabetes medications except metformin (unless stopped two weeks prior)
- Recent immunomodulatory treatment within 3 months before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Colorado Anschutz, Barbara Davis Center
Aurora, Colorado, United States, 80045
Actively Recruiting
Research Team
M
Morgan Sooy
CONTACT
H
Hali Broncucia
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here